| This article has been cited by |
| 1 | Ocular Side Effects of Bisphosphonates: A Review of Literature | |
| Nicholas A. Chartrand,Chap-Kay Lau,Mark T. Parsons,Jaiden J. Handlon,Yasmyne C. Ronquillo,Phillip C. Hoopes,Majid Moshirfar |
| Journal of Ocular Pharmacology and Therapeutics.2023;39(1)3 |
| [DOI] |
|
| 2 | Ocular Myasthenia Induced by Rivaroxaban in Patient with Deep Vein Thrombosis | |
| Enrique M. San Norberto,Irene García-Saiz,Diana Gutiérrez,Liliana Domingos,Carlos Vaquero |
| Annals of Vascular Surgery.2018;49(1)313.e1 |
| [DOI] |
|
| 3 | Risedronate-associated scleritis: a case report and review of the literature | |
| Iman Hemmati,John Wade,John Kelsall |
| Clinical Rheumatology.2012;31(9)1403 |
| [DOI] |
|
| 4 | Exacerbation of myasthenia gravis by alendronate | |
| S. Kesikburun,Ü. Güzelküçük,S. Alay,F. Yavuz,A. K. Tan |
| Osteoporosis International.2014;25(9)2319 |
| [DOI] |
|
| 5 | Adverse effects of bisphosphonates | |
| Luis Arboleya,Mercedes Alperi,Sara Alonso |
| Reumatología Clínica (English Edition).2011;7(3)189 |
| [DOI] |
|
| 6 | Selected lid problems in neurologic practice | |
| Gregory S. Kosmorsky,Alyssa Fiddler |
| Current Neurology and Neuroscience Reports.2009;9(5)390 |
| [DOI] |
|
| 7 | Efectos adversos de los bisfosfonatos | |
| Luis Arboleya,Mercedes Alperi,Sara Alonso |
| Reumatología Clínica.2011;7(3)189 |
| [DOI] |
|
| 8 | Neuromuscular Diseases and Bone | |
| Giovanni Iolascon,Marco Paoletta,Sara Liguori,Claudio Curci,Antimo Moretti |
| Frontiers in Endocrinology.2019;10(3)189 |
| [DOI] |
|
| 9 | Universal Nature of Drug Treatment Responses in Drug-Tissue-Wide Model-Animal Experiments Using Tensor Decomposition-Based Unsupervised Feature Extraction | |
| Yh. Taguchi,Turki Turki |
| Frontiers in Genetics.2020;11(3)189 |
| [DOI] |
|
| 10 | Drugs That Induce or Cause Deterioration of Myasthenia Gravis: An Update | |
| Shuja Sheikh,Usman Alvi,Betty Soliven,Kourosh Rezania |
| Journal of Clinical Medicine.2021;10(7)1537 |
| [DOI] |
|
